This brief summarizes public reporting and official announcements. Research findings may be preliminary. Talk to a qualified clinician before making health decisions.
The investigational drug DT120, an orally disintegrating form of LSD, met the primary endpoints in two Phase III trials for generalized anxiety disorder and major depressive disorder, MedPage Today reports. The article provides no results details and does not say the drug is approved.
HOW THIS BRIEF WAS MADE 1 outlet: 1 specialist. Automated sourcing and summaries by the BLUF engine. Corrections
If further review supports the findings, the drug could become a treatment option for people with these conditions. No U.S. approval or availability is reported.
The article does not say when the trial results will be published in detail or whether the company has sought regulatory approval.
Detailed trial results, including effect sizes and safety findings
Whether the drug’s developer seeks regulatory approval